This paper is only available as a PDF. To read, Please Download here.
Summary
Hepatocellular carcinoma (HCC) is a highly prevalent and lethal neoplasia, the management
of which has significantly improved during the last few years. A better knowledge
of the natural history of the tumor and the development of staging systems that stratify
patients according to the characteristics of the tumor, the liver disease, and the
performance status, such as the BCLC (Barcelona Clinic Liver Cancer) system, have
led to a better prediction of prognosis and to a most appropriate treatment approach.
Today curative therapies (resection, transplantation, ablation) can improve survival
in patients diagnosed at an early HCC stage and offer a potential long-term cure.
Patients with intermediate stage HCC benefit from chemoembolization and those diagnosed
at advanced stage benefit from sorafenib, a multikinase inhibitor with antiangiogenic
and antiproliferative effects. In this article we review the current management in
HCC and the new advances in this field.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of HepatologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.Int J Cancer. 2010; 127: 2893-2917
- Primary liver cancer: worldwide incidence and trends.Gastroenterology. 2004; 127: S5-S16
- Natural history of hepatitis-related hepatocellular carcinoma.World J Gastroenterol. 2008; 14: 1652-1656
- Natural history and prognostic factors for chronic hepatitis type B.Gut. 1991; 32: 294-298
- Hepatitis B e antigen and the risk of hepatocellular carcinoma.N Engl J Med. 2002; 347: 168-174
- Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection.J Clin Oncol. 2010; 28: 2437-2444
- A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China.Cancer Epidemiol Biomarkers Prev. 1994; 3: 3-10
- Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients.Gastroenterology. 1997; 112: 463-472
- Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death.Gut. 2000; 47: 131-136
- Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease.Gastroenterology. 2009; 136: 138-148
- Management of hepatocellular carcinoma: an update.Hepatology. 2011; 53: 1020-1022
- Alcoholic liver disease.Hepatology. 2010; 51: 307-328
- Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis.Hepatology. 2003; 37: 520-527
- Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus.Hepatology. 2002; 36: 1206-1213
- Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults.N Engl J Med. 2003; 348: 1625-1638
- Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma.Gastroenterology. 2004; 126: 460-468
- Insights into the pathogenesis and treatment of cancer from inborn errors of metabolism.Am J Hum Genet. 2011; 88: 402-421
- Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production.Science. 2007; 317: 121-124
- Principles of cancer screening: lessons from history and study design issues.Semin Oncol. 2010; 37: 202-215
- Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis.Aliment Pharmacol Ther. 2009; 30: 37-47
- Computed tomography-an increasing source of radiation exposure.N Engl J Med. 2007; 357: 2277-2284
- Serological surveillance for hepatocellular carcinoma: time to quit.J Hepatol. 2010; 52: 614-615
- Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial.J Hepatol. 2005; 43: 434-441
- Correlation between clinical indication for treatment and liver histology in HBeAg-negative chronic hepatitis B: a novel role of alpha-fetoprotein.Liver Int. 2010; 30: 1161-1168
- Alpha-fetoprotein-producing clear cell carcinoma of the extrahepatic bile ducts.J Clin Gastroenterol. 2006; 40: 555-557
- Clinicopathologic features and prognostic factors in alpha-fetoprotein-producing gastric cancers: analysis of 104 cases.J Surg Oncol. 2010; 102: 249-255
- Measurement of serum levels of des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma by a revised enzyme immunoassay kit with increased sensitivity.Cancer. 1999; 85: 812-818
- Desgamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients.Hepatology. 2003; 37: 1114-1121
- Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma.Gastroenterology. 2003; 125: 89-97
- Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma.Gastroenterology. 2009; 137: 110-118
- Randomized controlled trial of screening for hepatocellular carcinoma.J Cancer Res Clin Oncol. 2004; 130: 417-422
- Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis.Gut. 2001; 48: 251-259
- Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance.Gastroenterology. 2004; 126: 1005-1014
- Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival.J Hepatol. 2010; 53: 291-297
- Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: A randomized trial comparing 3- and 6-month periodicities.Hepatology. 2011; 54: 1987-1997
- Early hepatocellular carcinoma and dysplastic nodules.Semin Liver Dis. 2005; 25: 133-142
- Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia.Hepatology. 2009; 49: 658-664
- The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma.J Hepatol. 2009; 50: 746-754
- Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma.Hepatology. 2008; 47: 97-104
Vilana R, Forner A, Bianchi L, Garcia-Criado A, Rimola J, de Lope CR, et al. Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound. Hepatology; 51:2020-2029.
- A comparison of trends in the incidence of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in the United States.Cancer Epidemiol Biomarkers Prev. 2006; 15: 1198-1203
- Changing international trends in mortality rates for liver, biliary and pancreatic tumours.J Hepatol. 2002; 37: 806-813
- Role of FDG-PET in the evaluation and staging of hepatocellular carcinoma with comparison of tumor size, AFP level, and histologic grade.Int Surg. 2010; 95: 67-75
- Current Strategy for Staging and Treatment: the BCLC Update and Future Prospects.Semin Liver Dis. 2010; 30: 61-74
- Prospective validation of the Barcelona Clinic Liver Cancer staging system.J Hepatol. 2006; 44: 723-731
- Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre.Gut. 2005; 54: 411-418
- Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort.Hepatology. 2005; 41: 707-716
- Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver.J Hepatol. 2001; 35: 421-430
- Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial.Lancet. 2002; 359: 1734-1739
- Sorafenib in advanced hepatocellular carcinoma.N Engl J Med. 2008; 359: 378-390
- Kojiro M Pathology of Hepatocellular. Wiley-Blackwell, Carcinoma2006
- Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan.Hepatology. 2000; 32: 1224-1229
- Percutaneous radiofrequency ablation for early-stage hepatocellular carcinoma as a first-line treatment: long-term results and prognostic factors in a large singleinstitution series.Eur Radiol. 2007; 17: 684-692
- Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less.Gut. 2005; 54: 1151-1156
- Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice?.Hepatology. 2008; 47: 82-89
- Treatment of hepatocellular carcinoma by percutaneous tumor ablation methods: Ethanol injection therapy and radiofrequency ablation.Gastroenterology. 2004; 127: S159-S166
- Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma.Hepatology. 2004; 40: 1352-1360
- A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma.Gastroenterology. 2005; 129: 122-130
- Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases.Cancer. 2005; 103: 1201-1209
- Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling.Hepatology. 2004; 40: 667-676
- Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets.Hepatology. 2007; 45: 42-52
- Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma.Cancer Res. 2009; 69: 7385-7392
- Design and endpoints of clinical trials in hepatocellular carcinoma.J Natl Cancer Inst. 2008; 100: 698-711
- Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma.Hepatology. 2002; 35: 1164-1171
- Transcatheter chemoembolization in the treatment of HCC in patients not eligible for curative treatments: midterm results of doxorubicin-loaded DC bead.Abdom Imaging. 2008; 33: 512-519
- Resultados actuales de la quimioembolización en pacientes con carcinoma hepatocelular. Impacto en práctica clinica e investigatión.Gastroenterol Hepatol. 2011; 34: 139-209
- Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis.AJR Am J Roentgenol. 2010; 194: 830-837
- A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma.Hepatology. 2010; 51: 1274-1283
- The surgical approach to HCC: our progress and results in Japan.Liver Transpl. 2004; 10: S46-S52
- Resection and liver transplantation for hepatocellular carcinoma.Semin Liver Dis. 2005; 25: 181-200
- Portal vein embolization before right hepatectomy: prospective clinical trial.Ann Surg. 2003; 237: 208-217
- Surgical strategies for hepatocellular carcinoma with special reference to anatomical hepatic resection and intraoperative contrast-enhanced ultrasonography.Oncology. 2010; 78: 125-130
- Comparison of the outcomes between an anatomical subsegmentectomy and a non-anatomical minor hepatectomy for single hepatocellular carcinomas based on a Japanese nationwide survey.Surgery. 2008; 143: 469-475
- Anatomic resection independently improves long-term survival in patients with T1-T2 hepatocellular carcinoma.Ann Surg Oncol. 2007; 14: 1356-1365
- Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy.J Hepatol. 2003; 38: 200-207
- Prognostic impact of anatomic resection for hepatocellular carcinoma.Ann Surg. 2005; 242: 252-259
- Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinoma: a prospective randomized trial.Ann Surg. 2007; 245: 36-43
- Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma.Cancer. 2000; 89: 500-507
- A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma.Gastroenterology. 2009; 137: 850-855
- Laparoscopic versus open liver resection for hepatocellular carcinoma in patients with histologically proven cirrhosis: short- and middle-term results.Surg Endosc. 2007; 21: 2004-2011
- Meta-analysis of laparoscopic versus open resection for hepatocellular carcinoma.Dig Dis Sci. 2011; 56: 1937-1943
- Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies.J Hepatol. 2006; 44: 217-231
- Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation.Hepatology. 1999; 30: 1434-1440
- Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma.Gastroenterology. 2008; 134: 1908-1916
- Clinical practice guidelines for hepatocellular carcinoma: the first evidence based guidelines from Japan.World J Gastroenterol. 2006; 12: 828-829
- Prediction of microvascular invasion before curative resection of hepatocellular carcinoma.J Surg Oncol. 2008; 97: 246-252
- The predictors of microvascular invasion in candidates for liver transplantation with hepatocellular carcinoma-with special reference to the serum levels of des-gamma-carboxy prothrombin.J Surg Oncol. 2007; 95: 235-240
- Microvascular invasion in hepatocellular carcinoma: is it predictable with pretransplant MRI?.AJR Am J Roentgenol. 2011; 196: 1083-1089
- Predictors of microvascular invasion before hepatectomy for hepatocellular carcinoma.J Surg Oncol. 2010; 102: 462-468
- Predictor for histological microvascular invasion of hepatocellular carcinoma: a lesson from 229 consecutive cases of curative liver resection.World J Surg. 2010; 34: 1034-1038
- Predictive factors of microvascular invasion in patients with hepatocellular carcinoma larger than 5 cm.World J Surg. 2008; 32: 2218-2222
- Predictors of microvascular invasion in patients with hepatocellular carcinoma who are candidates for orthotopic liver transplantation.J Gastrointest Surg. 2002; 6: 224-232; discussion 232
- Overexpression of osteopontin independently correlates with vascular invasion and poor prognosis in patients with hepatocellular carcinoma.Hum Pathol. 2008; 39: 1777-1783
- Alpha-fetoprotein and tumour size are associated with microvascular invasion in explanted livers of patients undergoing transplantation with hepatocellular carcinoma.HPB (Oxford). 2010; 12: 56-61
- Gene-expression signature of vascular invasion in hepatocellular carcinoma.J Hepatol. 2011; 55: 1325-1331
- A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria.Ann Surg. 2010; 252: 903-912
- A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma.Ann Surg. 2006; 243: 321-328
- Transarterial chemoembolization in very early and early-stage hepatocellular carcinoma patients excluded from curative treatment: A prospective cohort study.Eur J Radiol. 2011;
- Hepatic resection versus radiofrequency ablation for very early stage hepatocellular carcinoma: a Markov model analysis.Hepatology. 2010; 51: 1284-1290
- High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: an indication for salvage liver transplantation.Liver Transpl. 2004; 10: 1294-1300
- Benefit of initial resection of hepatocellular carcinoma followed by transplantation in case of recurrence: An intention-to-treat analysis.Hepatology. 2012; 55: 132-140
- Gene expression in fixed tissues and outcome in hepatocellular carcinoma.N Engl J Med. 2008; 359: 1995-2004
- What should physicians look for in evaluating prognostic gene-expression signatures?.Nat Rev Clin Oncol. 2010; 7: 327-334
- A prospective, randomized, controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma.Ann Surg. 2009; 249: 195-202
- Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial.Lancet. 1999; 353: 797-801
- Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial.Lancet. 2000; 356: 802-807
- Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group.N Engl J Med. 1996; 334: 1561-1567
- Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis.Br J Surg. 2009; 96: 975-981
- Meta-analysis: interferon-alpha prevents the recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma.J Viral Hepat. 2010; 17: 287-292
- Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): a metaregression approach.J Hepatol. 2010; 52: 889-894
- Hepatic resection versus transplantation for hepatocellular carcinoma.Ann Surg. 1991; 214 (discussion 228-229.): 221-228
- Surgical treatment of hepatocellular carcinoma in cirrhosis: liver resection or transplantation?.Transplant Proc. 1993; 25: 1066-1067
- Role of liver transplantation in cancer therapy.Ann Surg. 1985; 202: 401-407
- Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis.N Engl J Med. 1996; 334: 693-699
- Liver transplantation for small hepatocellular carcinoma: the tumor-nodemetastasis classification does not have prognostic power.Hepatology. 1998; 27: 1572-1577
- Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis.Hepatology. 2001; 33: 1080-1086
- Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival.Hepatology. 2001; 33: 1394-1403
- Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis: a reasonable strategy?.Ann Surg. 2003; 238 (discussion 518-509.): 508-518
- Liver organ allocation for hepatocellular carcinoma: are we sure?.Liver Transpl. 2003; 9: 693-696
- Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma.Ann Surg. 2004; 239: 150-159
- Impact of UCSF criteria according to pre- and post-OLT tumor features: analysis of 479 patients listed for HCC with a short waiting time.Liver Transpl. 2006; 12: 1761-1769
- Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA.Ann Surg. 2007; 246 (discussion 509-511.): 502-509
- Expanded criteria for liver transplantation in patients with hepatocellular carcinoma: a report from the International Registry of Hepatic Tumors in Liver Transplantation.Liver Transpl. 2007; 13: 391-399
- Liver transplantation in patients with hepatocellular carcinoma across Milan criteria.Liver Transpl. 2008; 14: 272-278
- Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma.Liver Transpl. 2008; 14: 1107-1115
- Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis.Lancet Oncol. 2009; 10: 35-43
- Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters.Ann Surg. 2002; 235: 533-539
- Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States.Liver Transpl. 2010; 16: 262-278
- A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: implications for the current organ allocation policy.Liver Transpl. 2003; 9: 684-692
- Drop-out rates of patients with hepatocellular cancer listed for liver transplantation: outcome with chemoembolization.Liver Transpl. 2004; 10: 449-455
- Waiting list removal rates among patients with chronic and malignant liver diseases.Am J Transplant. 2006; 6: 1416-1421
- Hepatocellular carcinoma patients are advantaged in the current liver transplant allocation system.Am J Transplant. 2010; 10: 1643-1648
- Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation.Liver Transpl. 2007; 13: 122-129
- Applicability of adult-to-adult living donor liver transplantation.J Hepatol. 2005; 43: 104-109
- Donor morbidity after living donation for liver transplantation.Gastroenterology. 2008; 135: 468-476
- Living-donor liver transplantation for hepatocellular carcinoma.Transplantation. 2003; 75: S37-S40
- Living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan.Ann Surg. 2004; 240 (discussion 459-461.): 451-459
- Adult living donor liver transplantation for patients with hepatocellular carcinoma: extending UNOS priority criteria.Ann Surg. 2004; 239: 142-149
- Expansion of selection criteria for patients with hepatocellular carcinoma in living donor liver transplantation.Liver Transpl. 2007; 13: 1637-1644
- Living donor liver transplantation of the right lobe for hepatocellular carcinoma in cirrhosis in a European center.Liver Transpl. 2007; 13: 896-903
- Hepatocellular carcinoma recurrence and death following living and deceased donor liver transplantation.Am J Transplant. 2007; 7: 1601-1608
- Living donor liver transplantation for early hepatocellular carcinoma: A life-expectancy and cost-effectiveness perspective.Hepatology. 2001; 33: 1073-1079
- Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation.Gut. 2002; 50: 123-128
- Management of hepatocellular carcinoma on the waiting list before liver transplantation: time for controlled trials?.Liver Transpl. 2007; 13: S27-S35
- A model to predict survival in patients with end-stage liver disease.Hepatology. 2001; 33: 464-470
- The new liver allocation system: moving toward evidence-based transplantation policy.Liver Transpl. 2002; 8: 851-858
- Loco-regional treatment of hepatocellular carcinoma.Hepatology. 2010; 52: 762-773
- Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection.Radiology. 2003; 228: 235-240
- Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: A randomized controlled trial.Scand J Gastroenterol. 2008; 43: 727-735
- Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection.Radiology. 1999; 210: 655-661
- Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: a meta-analysis.J Hepatol. 2010; 52: 380-388
- Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies.Hepatology. 2009; 49: 453-459
- Radiofrequency thermal ablation vs. percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of randomized controlled trials.Am J Gastroenterol. 2009; 104: 514-524
- Needle track seeding following percutaneous procedures for hepatocellular carcinoma.World J Hepatol. 2009; 1: 62-66
- Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation.Radiology. 2005; 234: 961-967
- Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma-a randomized controlled trial.Gastroenterology. 1988; 94: 453-456
- A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma.N Engl J Med. 1995; 332: 1256-1261
- Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution.Hepatology. 1998; 27: 1578-1583
- Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC.J Hepatol. 1998; 29: 129-134
- Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival.Hepatology. 2003; 37: 429-442
- Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials.Radiology. 2002; 224: 47-54
- Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma.Cochrane Database Syst Rev. 2011; 3: CD004787
- Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies.Cardiovasc Intervent Radiol. 2007; 30: 6-25
- Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics].Hepatol. 2007; 46: 474-481
- Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: Results of the PRECISION V Study.Cardiovasc Intervent Radiol. 2010; 33: 41-52
- Hepatic tumors: predisposing factors for complications of transcatheter oily chemoembolization.Radiology. 1996; 198: 33-40
- A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma.Cancer. 2002; 94: 1747-1752
- Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?.Cancer. 2009; 115: 616-623
- Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.Semin Liver Dis. 2010; 30: 52-60
- Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes.Gastroenterology. 2010; 138: 52-64
- Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma.Gastroenterology. 2011; 140: 497-507 e492
- Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis.Hepatology. 2008; 47: 71-81
- Hallmarks of cancer: the next generation.Cell. 2011; 144: 646-674
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.Lancet Oncol. 2009; 10: 25-34
- Cetuximab for the treatment of colorectal cancer.N Engl J Med. 2007; 357: 2040-2048
- Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.N Engl J Med. 2006; 355: 2542-2550
- Molecular targeted therapies in hepatocellular carcinoma.Hepatology. 2008; 48: 1312-1327
- Targeted therapies for hepatocellular carcinoma.Gastroenterology. 2011; 140: 1410-1426
- Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon.N Engl J Med. 2008; 359: 2429-2441
- Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C.Gastroenterology. 2011; 140: 1990-1999
- Hepatocellular carcinoma.Lancet. 2012; (in press.)
Article info
Identification
Copyright
© 2012 European Association for the Study of the Liver. Published by Elsevier Inc. All rights reserved.
